In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Rebecca L SimkinDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0001-8093-2139 Aurélie Paulo-RamosDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0009-0000-3150-4453 Qiuhan LangDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0003-3880-1105 Elena R RhymesDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-7103-5513 Sunaina SuranaDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-7017-3105 David Villarroel-CamposDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0003-4250-7216 Sijiang LiuDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0009-0006-7235-3237 Roberto BellantiDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0003-4543-0162 Vlada DrotsevitchUK Dementia Research Institute, University College London, London, UK.
Owen SwannUK Dementia Research Institute, University College London, London, UK.
Michael P LunnDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0003-3174-6027 James N SleighDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-3782-9045 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Charcot-Marie-Tooth disease type 2D (CMT2D) results from gain-of-function mutations in
Indexed as
aminoacyl-tRNA synthetase (ARS)biomarkerCharcot-Marie-Tooth disease (CMT)motor neuronneuromuscular junction (NMJ)peripheral neuropathysensory neuron
Identifiers
PMID42465429
PMCPMC13370441
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390